Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...